Voltar
Artigo Acesso aberto Revisado por pares
BIBTEX RIS

Repression of BET activity sensitizes homologous recombination–proficient cancers to PARP inhibition

2017; American Association for the Advancement of Science; Volume: 9; Issue: 400 Linguagem: Inglês

10.1126/scitranslmed.aal1645

ISSN

1946-6242

Autores

Lu Yang, Youyou Zhang, Weiwei Shan, Zhongyi Hu, Jiao Yuan, Jingjiang Pi, Yueying Wang, Lingling Fan, Zhaoqing Tang, Chunsheng Li, Xiaowen Hu, János L. Tanyi, Yi Fan, Qihong Huang, Kathleen T. Montone, Chi V. Dang, Lin Zhang,

Tópico(s)

PARP inhibition in cancer therapy

Resumo

PARP inhibitors can be combined with BET inhibitors to treat cancers with de novo or acquired resistance to PARP inhibition.

Referência(s)